On page 13 of the original FDA briefing document the relative risk reduction of MOV compared to placebo was reported as 52% (95% CI: 33%, 80%); however, the statement should read, “Relative risk reduction of MOV compared to placebo was 48% (95% CI: 20%, 67%) based on the Cochran-Mantel-Haenszel method stratified by time of COVID-19 symptom onset (≤3 days versus >3 [4 to 5] days).”